Cost-effectiveness of hepatitis C treatment using generic direct-acting antivirals available in India.
<h4>Background & aims</h4>Availability of directly-acting antivirals (DAAs) has changed the treatment landscape of hepatitis C virus (HCV) infection. The high price of DAAs has restricted their use in several countries. However, in some countries such as India, generic DAAs are avail...
Saved in:
| Main Authors: | Rakesh Aggarwal, Qiushi Chen, Amit Goel, Nicole Seguy, Razia Pendse, Turgay Ayer, Jagpreet Chhatwal |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2017-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0176503&type=printable |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Economic evaluation of pan-genotypic generic direct-acting antiviral regimens for treatment of chronic hepatitis C in Iran: a cost-effectiveness study
by: Seyed Moayed Alavian, et al.
Published: (2022-06-01) -
Direct Acting Antivirals for the Treatment of Chronic Viral Hepatitis
by: Peter Karayiannis
Published: (2012-01-01) -
Medicaid and Medicare Utilization of Direct-Acting Antiviral Medications for Patients With Hepatitis C
by: Xiaohan Ying, et al.
Published: (2025-01-01) -
Direct Acting Antivirals in Patients with Chronic Hepatitis C and Down Syndrome
by: Eric R. Yoo, et al.
Published: (2016-01-01) -
Impact of hepatitis C virus genotype on the efficacy of the direct-acting antivirals in chronic kidney disease patients in West Bengal, India
by: Sagnik Bakshi, et al.
Published: (2025-05-01)